Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy

Author(s):  
Xue Feng ◽  
Flora Berklein ◽  
Pallavi B. Rane ◽  
Mohdhar Habib ◽  
Pei-Jung Lin
2020 ◽  
Vol 14 (4) ◽  
pp. 599-600
Author(s):  
Nihar Desai ◽  
Pallavi Rane ◽  
Sasikiran Nunna ◽  
Chi-Chang Chen ◽  
Jason Exter ◽  
...  

2020 ◽  
Vol 9 (1) ◽  
Author(s):  
Shirley X. Liao ◽  
Lucas Henneman ◽  
Cory Zigler

AbstractMarginal structural models (MSM) with inverse probability weighting (IPW) are used to estimate causal effects of time-varying treatments, but can result in erratic finite-sample performance when there is low overlap in covariate distributions across different treatment patterns. Modifications to IPW which target the average treatment effect (ATE) estimand either introduce bias or rely on unverifiable parametric assumptions and extrapolation. This paper extends an alternate estimand, the ATE on the overlap population (ATO) which is estimated on a sub-population with a reasonable probability of receiving alternate treatment patterns in time-varying treatment settings. To estimate the ATO within an MSM framework, this paper extends a stochastic pruning method based on the posterior predictive treatment assignment (PPTA) (Zigler, C. M., and M. Cefalu. 2017. “Posterior Predictive Treatment Assignment for Estimating Causal Effects with Limited Overlap.” eprint arXiv:1710.08749.) as well as a weighting analog (Li, F., K. L. Morgan, and A. M. Zaslavsky. 2018. “Balancing Covariates via Propensity Score Weighting.” Journal of the American Statistical Association 113: 390–400, https://doi.org/10.1080/01621459.2016.1260466.) to the time-varying treatment setting. Simulations demonstrate the performance of these extensions compared against IPW and stabilized weighting with regard to bias, efficiency, and coverage. Finally, an analysis using these methods is performed on Medicare beneficiaries residing across 18,480 ZIP codes in the U.S. to evaluate the effect of coal-fired power plant emissions exposure on ischemic heart disease (IHD) hospitalization, accounting for seasonal patterns that lead to change in treatment over time.


Author(s):  
Sarah P. Pourali ◽  
Yasmin Gutierrez ◽  
Alison H. Kohn ◽  
Jeffrey R. Rajkumar ◽  
Madison E. Jones ◽  
...  

2021 ◽  
Vol 61 (4) ◽  
pp. 590-602
Author(s):  
Dionne M. Hines ◽  
Shweta Shah ◽  
Jasjit K. Multani ◽  
Rolin L. Wade ◽  
Dawn C. Buse ◽  
...  

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 8561-8561
Author(s):  
Eric S. Nadler ◽  
Anupama Vasudevan ◽  
Kalatu Davies ◽  
Yunfei Wang ◽  
Ann Johnson ◽  
...  

8561 Background: Atezolizumab plus chemotherapy was the first CIT combination regimen approved for 1L treatment of ES-SCLC in 2019. This study investigated patient characteristics and treatment patterns for patients with ES-SCLC receiving this regimen in the real-world community oncology setting. Methods: This was a retrospective study including adult patients diagnosed with ES-SCLC between 01-Oct-2018 (after IMpower 133 publication in NEJM Sep-2018) and 31-Dec-2019, with follow-up through 31-March-2020 using The US Oncology Network electronic health records data. Descriptive analyses of patient characteristics and treatment patterns were conducted, with Kaplan-Meier (K-M) methods used to assess time to treatment discontinuation (TTD) and time to next treatment/death (TTNT). Results: Of the 408 patients included in this study, 267 (71.4%) received atezo+carboplatin+etoposide (Atezo+Chemo), 80 (21.4%) received carboplatin+etoposide (Chemo only) and the rest received other regimens. The Atezo+Chemo patients in the real-world cohort compared with the IMpower 133 trial (n = 201) were older (median age 68 vs. 64 years) and included fewer males (45% vs. 64%), fewer white race (73% vs. 81%), more patients with brain metastases at baseline (23% vs. 9%), and more patients with worse ECOG (2/3) performance-status score (24% vs. 0%). The median follow-up, TTD, and TTNT in months (mo) for the real-world cohort are presented in the table alongside the best comparable measures reported for the trial. Conclusions: Most patients in this real-world ES-SCLC cohort received the Atezo+Chemo regimen in the 1L setting. While the follow-up was much shorter and patients had worse baseline characteristics (age, brain metastases, ECOG) in the real-world setting compared to the IMpower 133 trial, the real-world median TTD in this descriptive analysis was found to be in line with the median duration of treatment in the trial. Further research with longer follow-up comparing the real-world effectiveness of the CIT and chemo regimens is needed.[Table: see text]


Stroke ◽  
2016 ◽  
Vol 47 (suppl_1) ◽  
Author(s):  
Judith H Lichtman ◽  
Michael R Jones ◽  
Alice J Sheffet ◽  
George Howard ◽  
Yun Wang ◽  
...  

Background: Carotid endarterectomy (CEA) is the leading procedure for carotid stenosis, yet national data on trends in rates and outcomes are limited. We determined CEA rates among Medicare beneficiaries and evaluated mortality and readmission over 8 years. Methods: We used Medicare fee-for-service data to identify beneficiaries aged ≥65y who had their first CEA (ICD-9 38.12) from 2003-2010 and calculated annual rates per 100,000 person-years (PY). We fit mixed models to assess trends in patient-level outcomes, adjusting for demographics, comorbidities, and symptomatic status. We also evaluated hospital-level trends by calculating risk-standardized mortality (RSMR) and readmission (RSRR) rates. A spatial mixed model adjusted for age, sex, and race was fit to calculate county-specific risk-standardized CEA rates in 2003-2004. Results: There were 505,966 unique CEA hospitalizations. The annual number of CEA discharges decreased from 81,604 in 2003 to 47,597 in 2010 (42% decrease), though the patient characteristics remained largely similar. The national CEA rate was 283 per 100,000 PY in 2003, and there was considerable geographic variability (Figure A). This rate decreased each year to a low of 172 per 100,000 PY in 2010. The rate of stroke or death within 30 days decreased from 3.2 to 2.7%, with a significant adjusted annual reduction of 3% (Figure B). Annual reductions in other short- and long-term outcomes were similar, ranging from 2-3%. The median hospital-level 30-day RSMR decreased over time from 0.99 to 0.57%, while the variation between hospitals increased (interquartile range of 0.7-1.67 percentage points). The 30-day RSRR decreased from 11.0 to 10.1%, but there was more homogeneity across hospitals and years. Conclusions: CEA use among Medicare patients decreased dramatically from 2003-2010, while mortality and readmission outcomes improved. The relative importance of biological and sociological mechanisms for these trends merits further study.


Sign in / Sign up

Export Citation Format

Share Document